Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Internal Medicine

Pulmonary And Respiratory Medicine

Intention-To-Treat Analysis

Show all topics

DOI

10.1016/s0140-6736(21)00228-2